Could this be another Greencross

Could this be another Greencross? The size of the opportunity in the companion animal market is dangerous to underestimate. Those that passed up Greencross may have noticed they missed a 1600% gain over the last five years. But very few new stories in this niche come through. Next in line is Nexvet which is unlisted. Morgans is doing a pre-IPO round now, and plans to IPO it later in CY014. They have a suite of monoclonal antibodies which will compete with the tired old conventional pharmaceuticals. As a former Vet myself, the product appeal is obvious to me. Stateside the sector is riding the biotech wave, with Nexvet's Nasdaq peers jumping on IPO to then increase in multiples.

The Livewire Equities feed brings you a range of insights that relate to Australian equities


No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

trending on livewire
Get the best of Livewire by signing up to our popular daily newsletter